1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Godavari Drugs Limited

Godavari Drugs Limited

BBSE:GODAVARI
120.50
INR
-3.65
(-2.94%)
5.04EPS
23.68P/E
1.22BMarket Cap
Godavari Drugs Limited
BSE:GODAVARI
(Bombay Stock Exchange)

Recent

price

120.50

P/E

ratio

23.68

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
6.95
4.94
10.12
12.53
72.83
94.44
100.28
85.48
110.61
127.23
162.84
214.08
212.09
208.14
150.62
140.5
134.68
Revenue per Share
0.01
-2.12
0.64
2.06
4.84
1.79
2.4
1.1
1.6
2.66
5.48
6.97
5.03
7.37
5.82
5.43
5.09
Basic EPS, GAAP
0.37
- -
- -
-0.06
-8.04
-8.77
0.39
0.26
1.5
-0.86
-0.46
7.95
5.16
6.92
-11.7
-34.51
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12.05
- -
10.57
12.63
17.34
19.14
21.54
22.64
24.24
26.9
32.38
39.35
44.38
51.74
57.56
74.85
- -
Book Value per Share
12.05
- -
9.55
12.21
17.34
19.14
21.54
22.64
24.24
26.9
32.38
39.35
44.38
51.74
57.56
74.85
- -
Tangible Book Value per Share
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
Basic Weighted Avg Shares
52
37
76
94
548
711
756
644
835
957
1,227
1,611
1,596
1,567
1,134
1,058
1,100
Sales/Revenue/Turnover
2.65
-39.07
12.15
9.47
9.88
5.47
5.9
4.77
5.27
5.14
7.02
6.11
6.21
7.32
8.55
8.06
6.83
Operating Margin (%)
9
9
10
10
7
6
8
10
11
12
12
17
19
20
24
24
24
Depreciation Expense
- -
-16
5
16
36
14
18
8
12
20
41
52
38
55
44
41
42
Net Income, GAAP
21.21
- -
33
- -
22.96
37.97
33.19
36.88
30.78
12.59
27.66
25.29
23.28
19.83
22.14
19.24
15.79
Effective Tax Rate (%)
0.1
-42.95
6.32
16.45
6.65
1.9
2.39
1.29
1.45
2.09
3.37
3.26
2.37
3.54
3.86
3.86
3.78
Profit Margin (%)
30
- -
33
34
98
93
91
99
103
96
171
166
133
65
57
267
- -
Working Capital
14
- -
24
24
36
39
44
66
80
112
145
118
119
112
239
370
- -
LT Debt
91
- -
80
95
131
144
162
170
183
203
244
296
334
390
433
758
- -
Total Equity
0.87
- -
- -
- -
23.51
9.38
9.61
5.67
7.9
9.68
11.96
13.37
10.68
9.62
7.32
5.36
- -
Return on Invested Capital (%)
0.87
- -
- -
- -
24.71
9.42
9.64
5.12
7.02
8.4
11.05
12.09
8.34
9.16
7.19
5.22
- -
Return on Capital (%)
0.06
- -
- -
17.77
32.32
9.84
11.81
4.99
6.85
10.39
18.49
19.42
12.01
15.33
10.64
6.86
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
450
- -
LT Borrowings
- -
370
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
10
10
Market Capitalization
579
871
1,221

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,118
- -
Cash, Cash Equivalents & STI
- -
120
- -
Accounts Receivable, Net
- -
436
- -
Inventories
- -
461
- -
Total Current Liabilities
- -
851
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
450
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.31%
27.4%
74.87%
Free Cash Flow
-178.22%
-382.64%
195.26%
Net Income, GAAP
21.54%
3.62%
-6.64%
Sales/Revenue/Turnover
5.82%
-1.15%
-6.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
322
261
296
255
1,134
2026
238
266
222
332
1,058
2027
280
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.17
1.45
1.02
1.19
5.82
2026
1.38
1.33
1.01
1.71
5.43
2027
1.1
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Godavari Drugs Limited manufactures active pharmaceutical ingredients, drug intermediates and fine chemicals for the global life science industry from its production facility in Nanded, Maharashtra; core products include Ciprofloxacin HCl USP/EP/BP/IP, Ciprofloxacin Base USP/EP/BP/IP, Ciprofloxacin Lactate IH, Ciprofloxacin Betaine IH, Mefenamic Acid USP/EP/BP/IP, Enrofloxacin USP/EP/BP/IP and Ethambutol HCl USP/BP/IP, with upcoming active pharmaceutical ingredients such as Carbamazepine and Oxcarbazepine, as well as intermediates including A D Lactone for Spironolactone and 6 Mercaptopurine for Azathioprine. The company, founded in 1987 and headquartered at Sardar Patel Road, Secunderabad, Telangana, provides contract manufacturing and loan license services to multinational clients including Dr. Reddy’s Laboratories for Ciprofloxacin and RPG Life Sciences for AD Lactone intermediate, focusing on antibiotic, anti-tuberculosis, anti-allergy, anti-HIV, nootropic, xanthine and anticonvulsant therapeutic segments with cGMP-compliant and WHO GMP-accredited operations. Godavari Drugs maintains active strategic tie-ups for manufacturing while pursuing expansions such as acquiring 17.5 acres of land in MIDC Krushnoor, Nanded District, for capacity enhancement and upgrading effluent treatment plant and reverse osmosis systems to support 105 cubic meters per day capacities.